Quick Answer
TransMedics Group, Inc. reported Stockholders Equity of $473.10 million for the year ending 2025.
- TransMedics Group, Inc. showed an increase of +107.0% in Stockholders Equity from 2024 to 2025.
- This data is from TransMedics Group, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$173.59 million | Q2 2018: -$179.66 million | Q3 2018: -$184.70 million | Q1 2019: -$199.04 million | Q2 2019: $71.16 million | Q3 2019: $63.47 million | Q1 2020: $46.68 million | Q2 2020: $113.76 million | Q3 2020: $109.55 million | Q1 2021: $97.68 million | Q2 2021: $88.98 million | Q3 2021: $78.55 million | Q1 2022: $59.91 million | Q2 2022: $50.92 million | Q3 2022: $187.86 million | Q1 2023: $192.63 million | Q2 2023: $145.21 million | Q3 2023: $126.46 million | Q1 2024: $159.47 million | Q2 2024: $189.89 million | Q3 2024: $209.92 million | Q1 2025: $266.31 million | Q2 2025: $318.10 million | Q3 2025: $355.20 million.
- Over the full 9 years of available data (2017 to 2025), TransMedics Group, Inc.'s Stockholders Equity has grown by 380.4%.
- Historical annual values: Fiscal year 2025: $473.10 million | Fiscal year 2024: $228.60 million | Fiscal year 2023: $137.20 million | Fiscal year 2022: $187.38 million | Fiscal year 2021: $67.85 million | Fiscal year 2020: $103.89 million | Fiscal year 2019: $54.65 million | Fiscal year 2018: -$192.24 million | Fiscal year 2017: -$168.72 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: